Žádné připojení k internetu — zobrazuje se uložená verze stránky.

Mesoblast Ltd

USUSD
← Do screeneru

Mesoblast Ltd (US:MEOBF) — Biotechnology: Biological Products (No Diagnostic Substances). Počet burz, na kterých se obchodují akcie společnosti: 2. Na této stránce — cena a graf, dividendy, největší akcionáři a historie počtu akcií.

O společnosti

Web
mesoblast.com
Sektor
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Sídlo
MELBOURNE, VICTORIA, Australia
Generální ředitel
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Zaměstnanci
108
Akcie v oběhu
1.3 mld. k 2026-06-30
Volně obchodovatelné akcie
861.1 mil.
Tržní kapitalizace
1.48 mld. USD
Insideři
36.28%
Instituce
17.44%
Odvětví (SIC)
Biological Products, (No Diagnostic Substances)
ISIN
AU000000MSB8
Popis

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Burzy a tickery

BurzaTickerMěnaCenaTyp
US USA StocksMEOBFUSD1.39 +21.93%kmenové akcie
AU Australian Securities ExchangeMSBAUD—kmenové akcie

Cena za 3 měsíce

den růstu den poklesu ex-dividendový den den výplatyNajeďte / klepněte na den — otevírací, závěrečná, nejvyšší a nejnižší cena

Dividendy

Nebyly nalezeny žádné výplaty dividend (zkontrolováno 07.10.2026). Společnost pravděpodobně nevyplácí dividendy.

Zprávy tento týden

Zatím žádné zprávy z webu společnosti.

reklama

Největší držitelé

DržitelPodílAkcieDatum zprávy
Itescu (Silviu) (Chief E…≈6.23%80.84 mil.2026-07-17
VANGUARD STAR FUNDS-Vang…1.05%13.66 mil.2026-04-30
VANGUARD TAX-MANAGED FUN…0.62%8.01 mil.2026-06-30
iShares Trust-iShares Co…0.53%6.88 mil.2026-07-31
Rose (Eric) (Director (N…≈0.52%6.75 mil.2026-01-09
DFA INVESTMENT TRUST CO-…0.36%4.68 mil.2026-04-30
VANGUARD Intl Eqy. INDEX…0.27%3.51 mil.2026-04-30
iShares Trust-iShares MS…0.24%3.07 mil.2026-07-31
SCHWAB STRATEGIC TRUST-S…0.15%1.99 mil.2026-05-31
Dimensional ETF Trust-Di…0.11%1.38 mil.2026-04-30
iShares Trust-iShares Co…0.09%1.23 mil.2026-07-31
SPDR INDEX SHARES Fd.S-S…0.09%1.19 mil.2026-08-31
Bell (Jane Catherine) (D…≈0.05%622 4922025-02-28
Burns (William) (Indepen…≈0.02%226 2502025-10-21
Legato Capital Managemen…0.01%47 3802022-06-30
Cobley (Lyn Elizabeth) (…≈0%63 0002026-01-09